Brokerages Set Definium Therapeutics, Inc. (NASDAQ:DFTX) Price Target at $35.70

Definium Therapeutics, Inc. (NASDAQ:DFTX) has earned a consensus recommendation of “Buy” from the twelve brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $35.70.

DFTX has been the subject of a number of analyst reports. JonesTrading started coverage on Definium Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. Chardan Capital upgraded shares of Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. HC Wainwright increased their price target on shares of Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Jefferies Financial Group began coverage on shares of Definium Therapeutics in a research report on Thursday, January 29th. They set a “buy” rating and a $30.00 price target on the stock.

Insider Transactions at Definium Therapeutics

In related news, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $339,151.65. Following the completion of the transaction, the chief executive officer owned 778,477 shares of the company’s stock, valued at approximately $10,236,972.55. This represents a 3.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Daniel Karlin sold 5,600 shares of the stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $73,640.00. Following the transaction, the insider owned 425,025 shares in the company, valued at $5,589,078.75. This represents a 1.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 42,667 shares of company stock valued at $561,071 in the last ninety days. 2.26% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in DFTX. Russell Investments Group Ltd. lifted its position in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares in the last quarter. BIT Capital GmbH purchased a new stake in Definium Therapeutics in the 3rd quarter worth $26,000. Fifth Third Bancorp raised its position in Definium Therapeutics by 5,593.2% during the third quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after acquiring an additional 3,300 shares during the period. Sound Income Strategies LLC acquired a new position in Definium Therapeutics during the third quarter worth $46,000. Finally, BNP Paribas Financial Markets lifted its holdings in Definium Therapeutics by 56.0% during the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after purchasing an additional 3,020 shares in the last quarter. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Stock Performance

NASDAQ DFTX opened at $18.06 on Wednesday. The firm has a market capitalization of $1.78 billion, a P/E ratio of -8.48 and a beta of 2.56. The stock has a 50-day simple moving average of $16.58 and a two-hundred day simple moving average of $13.38. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.29 and a current ratio of 6.29. Definium Therapeutics has a fifty-two week low of $4.70 and a fifty-two week high of $19.62.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.